These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. IMAB showed earnings on August 20, 2025. You can read more about the earnings report here.
a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.